Objective To investigate the anti-inflammatory, antioxidant and anti-arthritic effects of Centello asiatica methanolfraction （CAME） on collagen-induced arthritis （ClA）, an animal model of rheumatoid arthritis. Met...Objective To investigate the anti-inflammatory, antioxidant and anti-arthritic effects of Centello asiatica methanolfraction （CAME） on collagen-induced arthritis （ClA）, an animal model of rheumatoid arthritis. Methods Arthritis was induced in female wistar rats by immunization with porcine type II collagen. The CIA rats were treated orally with CaME （50, 150, and 250 mg/kg/day） for 15 d （beginning on day 21 of the experimental period）. The clinical, histological, biochemical, and immunological parameters were assessed. Results CaME treatment （150 and 250 mg/kg） significantly attenuated the severity of CIA and reduced the synovial inflammation, cartilage erosion, and bone erosion as evident from both histological and radiographic data. The escalated plasma levels of pro-inflammatory cytokines TNF-α, IL-1β, IL-6, and IL-12 alongwith nitric oxide in CIA rats decreased significantly on CaME treatment. The serum levels of type-Ⅱ collagen antibody were significantly lower in rats of CaME （150 and 250 mg/kg） treated group than those in the arthritic group. Furthermore, by inhibiting the above mediators, CaME also contributed towards the reversal of the disturbed antioxidant levels and peroxidative damage. Conclusion Our results clearly indicate that oral administration of CaME suppresses joint inflammation, cytokine expression as well as antioxidant imbalance, thereby contributing to an amelioration of arthritis severity in CIA rats.展开更多
Acute Lung Injury(ALI)and its severe form Acute Respiratory Distress Syndrome(ARDS)are the major cause of ICU death worldwide.ALI/ARDS is characterized by severe hypoxemia and inflammation that leads to poor lung comp...Acute Lung Injury(ALI)and its severe form Acute Respiratory Distress Syndrome(ARDS)are the major cause of ICU death worldwide.ALI/ARDS is characterized by severe hypoxemia and inflammation that leads to poor lung compliance.Despite many advances in understanding and management,ALI/ARDS is still causing significant morbidity and mortality.Long non-coding RNA(lncRNA)is a fast-growing topic in lung inflammation and injury.lncRNA is a class of non-coding RNA having a length of more than 200 nucleotides.It has been a center of research for understanding the pathophysiology of various diseases in the past few years.Multiple studies have shown that lncRNAs are abundant in acute lung injury/injuries in mouse models and cell lines.By targeting these long non-coding RNAs,many investigators have demonstrated the alleviation of ALI in various mouse models.Therefore,lncRNAs show great promise as a therapeutic target in ALI.This review provides the current state of knowledge about the relationship between lncRNAs in various biological processes in acute lung injury and its use as a potential therapeutic target.展开更多
SPECIAL ISSUE INTRODUCTION Targeted therapies in cancer aim to specifically block the activity of crucial proteins or signaling pathways necessary for the growth and/or survival of tumor cells.A major breakthrough in ...SPECIAL ISSUE INTRODUCTION Targeted therapies in cancer aim to specifically block the activity of crucial proteins or signaling pathways necessary for the growth and/or survival of tumor cells.A major breakthrough in targeted cancer therapy was the introduction nearly two decades ago of imatinib,an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myeloid leukemia.Over the last years,significant advances in our understanding of tumor biology have facilitated the development of many drugs targeting not only kinases,but also other protein families and cellular processes.Several of these agents are currently employed or being implemented for the treatment of different hematologic and solid malignancies,such as lung cancer.The special issue on“Targeted cancer therapy”will include reviews and commentaries updating the clinical use of targeted agents in the treatment of different tumor types,and the mechanisms that underlie the action of drugs directed to different types of targets.The special issue will also include research articles presenting novel outstanding data on all aspects of targeted cancer therapy.All submissions will undergo rigorous peer review and will be published free of charge upon acceptance.展开更多
基金financial assistance received from University Grants Commission to undertake the present study
文摘Objective To investigate the anti-inflammatory, antioxidant and anti-arthritic effects of Centello asiatica methanolfraction （CAME） on collagen-induced arthritis （ClA）, an animal model of rheumatoid arthritis. Methods Arthritis was induced in female wistar rats by immunization with porcine type II collagen. The CIA rats were treated orally with CaME （50, 150, and 250 mg/kg/day） for 15 d （beginning on day 21 of the experimental period）. The clinical, histological, biochemical, and immunological parameters were assessed. Results CaME treatment （150 and 250 mg/kg） significantly attenuated the severity of CIA and reduced the synovial inflammation, cartilage erosion, and bone erosion as evident from both histological and radiographic data. The escalated plasma levels of pro-inflammatory cytokines TNF-α, IL-1β, IL-6, and IL-12 alongwith nitric oxide in CIA rats decreased significantly on CaME treatment. The serum levels of type-Ⅱ collagen antibody were significantly lower in rats of CaME （150 and 250 mg/kg） treated group than those in the arthritic group. Furthermore, by inhibiting the above mediators, CaME also contributed towards the reversal of the disturbed antioxidant levels and peroxidative damage. Conclusion Our results clearly indicate that oral administration of CaME suppresses joint inflammation, cytokine expression as well as antioxidant imbalance, thereby contributing to an amelioration of arthritis severity in CIA rats.
文摘Acute Lung Injury(ALI)and its severe form Acute Respiratory Distress Syndrome(ARDS)are the major cause of ICU death worldwide.ALI/ARDS is characterized by severe hypoxemia and inflammation that leads to poor lung compliance.Despite many advances in understanding and management,ALI/ARDS is still causing significant morbidity and mortality.Long non-coding RNA(lncRNA)is a fast-growing topic in lung inflammation and injury.lncRNA is a class of non-coding RNA having a length of more than 200 nucleotides.It has been a center of research for understanding the pathophysiology of various diseases in the past few years.Multiple studies have shown that lncRNAs are abundant in acute lung injury/injuries in mouse models and cell lines.By targeting these long non-coding RNAs,many investigators have demonstrated the alleviation of ALI in various mouse models.Therefore,lncRNAs show great promise as a therapeutic target in ALI.This review provides the current state of knowledge about the relationship between lncRNAs in various biological processes in acute lung injury and its use as a potential therapeutic target.
文摘SPECIAL ISSUE INTRODUCTION Targeted therapies in cancer aim to specifically block the activity of crucial proteins or signaling pathways necessary for the growth and/or survival of tumor cells.A major breakthrough in targeted cancer therapy was the introduction nearly two decades ago of imatinib,an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myeloid leukemia.Over the last years,significant advances in our understanding of tumor biology have facilitated the development of many drugs targeting not only kinases,but also other protein families and cellular processes.Several of these agents are currently employed or being implemented for the treatment of different hematologic and solid malignancies,such as lung cancer.The special issue on“Targeted cancer therapy”will include reviews and commentaries updating the clinical use of targeted agents in the treatment of different tumor types,and the mechanisms that underlie the action of drugs directed to different types of targets.The special issue will also include research articles presenting novel outstanding data on all aspects of targeted cancer therapy.All submissions will undergo rigorous peer review and will be published free of charge upon acceptance.
